Search Results

You are looking at 181 - 190 of 814 items for :

  • "metastases" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

participants will be enrolled in this multicenter study. Primary Objective: Determine progression-free survival (PFS) [time frame: start of induction, osimertinib up to 22 months] Secondary Objectives: Determine time to appearance of new metastases [time frame

Full access

Nan Du, Tian Xie, and Xinsheng Cheng

nomogram model was conducted based on the result of multivariate analyses including age, race, T stage, N stage, distant metastases. AUC was 0.769. Age was divided into 4 groups by using RCS, and the optimal cut-off points for age were 40, 52 and 60 years

Full access

be enrolled in this multicenter study. Primary Objective: Determine progression-free survival (PFS) [time frame: start of induction, osimertinib up to 22 months] Secondary Objectives: Determine time to appearance of new metastases [time frame: start

Full access

distant metastases compared with other breast cancer types. Effective targeted breast cancer strategies, including endocrine agents and HER2-directed therapies, are not active against these tumors. In the NCCN Guidelines, systemic chemotherapy is often

Full access

Gianfranco Puppo, Gian Paolo Mattioli, Sara De Magistris, Erilda Kamberi, Maria Serafini, Giordano Riccioni, Yuri Rosati, and Francesca Marchesani

with advanced NSCLC in a real-life context, the efficacy of the treatment was independent of the age. Factors associated with lower survival were the presence of brain or liver metastases or previous treatment with a tyrosine kinase inhibitor (TKI) drug.

Full access

Daniel T Cifarelli and Christopher P Cifarelli

months. Metastases and meningiomas comprised 60% of diagnoses. Median age was 62 years with median household income and residential population of $44,752 USD and 7634 people. The one-way mean and median travel distances were 74.6 and 66.3 miles. The total

Full access

R. Michael Tuttle and R. Leboeuf

with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy . J Clin Endocrinol Metab 2006 ; 91 : 2892 – 2899 . 6. Robbins RJ Wan Q Grewal RK . Real-time prognosis for metastatic

Full access

Supratentorial PNET AMED-2 Standard risk for recurrence The recommendations “Localized brain tumor (<1.5 cm 2 residual tumor); no spine metastases and negative CSF; no disseminated disease” changed to: ▪ No evidence of metastasis (brain, spine

Full access

Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Wells Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass

or accepted therapy. Principles of the Management of Metastatic Disease Approximately 50% to 60% of patients diagnosed with CRC develop colorectal metastases, 4 - 6 and 80% to 90% of these patients have unresectable metastatic liver disease

Full access

Jonathan M. Loree and Scott Kopetz

liver metastases RAS status appears high in colorectal cancer, ranging from 90% to 100%; however, discordance of up to 32% has been reported between lung or lymph node metastases and primary tumors. 7 , 8 In the reported case, a partial response was